Artivion Inc (AORT) Stock Price, Quote & News

Company Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THOR...

Industry: Medical Devices

Sector: Healthcare

Phone: 770 419 3355

Website: artivion.com

Address:

1655 Roberts Boulevard NW, Kennesaw, United States

BillionerOfKing Nov. 13 at 12:27 PM

$AORT Current Stock Price: $47.63 Contracts to trade: $50 AORT Nov 21 2025 Call Entry: $0.45 Exit: $0.82 ROI: 83% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

smartkarma Nov. 10 at 3:11 AM

$AORT | Primer: Artivion (AORT US) - Nov 2025 "Artivion is a niche leader in aortic repair, demonstrating strong revenue growth driven by its key product families: On-X mechanical heart..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-artivion-aort-us-nov-2025

0 · Reply

JarvisFlow Nov. 7 at 9:36 PM

Canaccord Genuity has updated their rating for Artivion ( $AORT ) to Buy with a price target of 51.

0 · Reply

StockConsultant Nov. 7 at 2:28 PM

$AORT Artivion stock, nice continuation breakout at https://stockconsultant.com/?AORT

0 · Reply

JarvisFlow Nov. 7 at 1:42 PM

Citizens has adjusted their stance on Artivion ( $AORT ), setting the rating to Market Outperform with a target price of 47 → 53.

0 · Reply

JarvisFlow Nov. 7 at 10:01 AM

Needham has updated their rating for Artivion ( $AORT ) to Buy with a price target of 58.

0 · Reply

Wigglyick Nov. 7 at 2:45 AM

$AORT another Algo-Doozio pick. Artivion , a med devise co that develope solutions addressing cardiac & vascular surgery challenges. Popped on August ER and based, breaking out again.

0 · Reply

Estimize Nov. 6 at 4:00 PM

$AORT reports after the close, Estimize Consensus +0.01 EPS and +0.40M Revs compared to WS http://www.estimize.com/aort/fq3-2025?utm_conten

0 · Reply

Doozio Oct. 18 at 3:34 PM

$AORT a say out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

BEATOFtheMARKET Oct. 9 at 2:44 PM

List 9/26/25 results $AORT $AOS $APD $APH 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

PI PLMR SMTC SPSC VRTX

Nov 6, 2025, 11:46 PM EST - 8 days ago

Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 8 days ago

Artivion Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:00 AM EST - 8 days ago

Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial

Oct 29, 2025, 4:10 PM EDT - 16 days ago

Artivion to Participate in the Stifel 2025 Healthcare Conference

Oct 23, 2025, 4:10 PM EDT - 22 days ago

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Sep 10, 2025, 5:03 PM EDT - 2 months ago

Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 5, 2025, 4:10 PM EDT - 2 months ago

Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:47 AM EDT - 2 months ago

Share Growth And Strong Clinical Results Continue To Support The Artivion Story

Aug 8, 2025, 2:30 PM EDT - 3 months ago

Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Artivion Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:10 PM EDT - 3 months ago

Artivion to Participate in Upcoming Investor Conferences

Jul 24, 2025, 4:10 PM EDT - 4 months ago

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results

May 28, 2025, 5:51 PM EDT - 6 months ago

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

May 14, 2025, 4:01 PM EDT - 6 months ago

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

May 5, 2025, 10:37 PM EDT - 6 months ago

Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:05 PM EDT - 6 months ago

Artivion Reports First Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 6 months ago

Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Apr 21, 2025, 4:10 PM EDT - 7 months ago

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

Mar 4, 2025, 4:05 PM EST - 9 months ago

Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Feb 24, 2025, 11:00 PM EST - 9 months ago

Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 9 months ago

Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 10, 2025, 4:10 PM EST - 9 months ago

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

Jan 27, 2025, 8:00 AM EST - 10 months ago

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

Dec 9, 2024, 10:52 AM EST - 1 year ago

US medical device giant Artivion says hackers stole files during cybersecurity incident

Dec 9, 2024, 8:00 AM EST - 1 year ago

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Nov 9, 2024, 12:02 PM EST - 1 year ago

Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Artivion Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 4:15 PM EDT - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

Oct 10, 2024, 4:10 PM EDT - 1 year ago

Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Aug 10, 2024, 2:45 PM EDT - 1 year ago

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Artivion Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 4:10 PM EDT - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Artivion Amends Agreements with Endospan

Jun 21, 2024, 5:01 PM EDT - 1 year ago

Data-Driven Growth Fuels More Upside For Overlooked Artivion

May 6, 2024, 10:47 PM EDT - 1 year ago

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:05 PM EDT - 1 year ago

Artivion Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:05 AM EDT - 1 year ago

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

Apr 22, 2024, 4:10 PM EDT - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

Apr 1, 2024, 4:10 PM EDT - 1 year ago

Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 4:10 PM EST - 1 year ago

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Feb 15, 2024, 8:22 PM EST - 1 year ago

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:05 PM EST - 1 year ago

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 1, 2024, 4:10 PM EST - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

Jan 29, 2024, 8:25 AM EST - 1 year ago

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

Jan 18, 2024, 4:05 PM EST - 1 year ago

Artivion Obtains $350 Million in Senior Secured Credit Facilities

ARES

Dec 6, 2023, 4:15 PM EST - 2 years ago

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.

Nov 9, 2023, 8:25 AM EST - 2 years ago

Artivion Announces Completion of Enrollment in PERSEVERE Trial

BillionerOfKing Nov. 13 at 12:27 PM

0 · Reply

smartkarma Nov. 10 at 3:11 AM

0 · Reply

JarvisFlow Nov. 7 at 9:36 PM

Canaccord Genuity has updated their rating for Artivion ( $AORT ) to Buy with a price target of 51.

0 · Reply

StockConsultant Nov. 7 at 2:28 PM

$AORT Artivion stock, nice continuation breakout at https://stockconsultant.com/?AORT

0 · Reply

JarvisFlow Nov. 7 at 1:42 PM

Citizens has adjusted their stance on Artivion ( $AORT ), setting the rating to Market Outperform with a target price of 47 → 53.

0 · Reply

JarvisFlow Nov. 7 at 10:01 AM

Needham has updated their rating for Artivion ( $AORT ) to Buy with a price target of 58.

0 · Reply

Wigglyick Nov. 7 at 2:45 AM

$AORT another Algo-Doozio pick. Artivion , a med devise co that develope solutions addressing cardiac & vascular surgery challenges. Popped on August ER and based, breaking out again.

0 · Reply

Estimize Nov. 6 at 4:00 PM

$AORT reports after the close, Estimize Consensus +0.01 EPS and +0.40M Revs compared to WS http://www.estimize.com/aort/fq3-2025?utm_conten

0 · Reply

Doozio Oct. 18 at 3:34 PM

$AORT a say out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

BEATOFtheMARKET Oct. 9 at 2:44 PM

List 9/26/25 results $AORT $AOS $APD $APH 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

IN0V8 Sep. 29 at 6:07 PM

$AORT Canaccord Genuity raises target price to $50 from $41 Stifel raises target price to $46 from $40

0 · Reply

JarvisFlow Sep. 29 at 2:55 PM

Stifel updates rating for Artivion ( $AORT ) to Buy, target set at 40 → 46.

0 · Reply

NVDAMillionaire Sep. 4 at 4:18 PM

$AORT Really good write-up that perfectly summarizes AORT's present situation. So if you want to bring your AORT knowledge up to date or just discover AORT, this is required reading. https://beyondspx.com/quote/AORT/artivion-s-aortic-ambition-a-growth-story-forged-by-innovation-and-strategic-deleveraging-nyse-aort#analysis

0 · Reply

FinJay Aug. 24 at 3:10 AM

$AORT https://youtu.be/D8scJx747fE

0 · Reply

EntryRaider Aug. 23 at 5:43 AM

$AORT Aortis Inc is a medical device company with innovative technology but unproven commercial adoption

0 · Reply

Albino_Trader123 Aug. 22 at 6:18 PM

$AORT Very clean chart. nice fundamentals and picture perfect breakout and nobody watching

0 · Reply

JarvisFlow Aug. 22 at 11:30 AM

Needham has updated their rating for Artivion ( $AORT ) to Buy with a price target of 50.

0 · Reply

stockanalysis_ Aug. 19 at 10:36 PM

After Hours Losers: $MEDP $AORT $LZB $JHX $GTLS Save this screener here: https://stockanalysis.com/markets/afterhours/losers/ Discount code SAVEONTRADING to pick up Stock Analysis for just $5.91/m.

0 · Reply

JarvisFlow Aug. 13 at 3:17 PM

Ladenburg Thalmann has updated their rating for Artivion ( $AORT ) to Neutral with a price target of 38.8.

0 · Reply

souldout Aug. 11 at 11:32 AM

$ATR AMS Advanced Medical Solutions on LSE sounds like buyout on way according to Betaville $AORT $ZBH https://www.betaville.co.uk/betaville-intelligence/8el8u1xa2w960e6jtj9hmghf9czy1cwlu45j

0 · Reply

Doozio Aug. 8 at 6:24 PM

Yo $AORT a say it was always during 🐒🍌🧠⏰♾️

0 · Reply

Knot2 Aug. 8 at 5:44 PM

$AORT hedges shorted the launch

0 · Reply

Market Cap	2.16B
Revenue (ttm)	388.54M
Net Income (ttm)	-13.36M
EPS (ttm)	N/A
PE Ratio	103.54
Forward PE	79.38
Profit Margin	-3.44%
Debt to Equity Ratio	0.49

Volume	540,700
Avg Vol	404,480
Day's Range	N/A - N/A
Shares Out	47.38M
Stochastic %K	43%
Beta	1.65
Analysts	Strong Sell
Price Target	$51.71